Holen Sie sich die Stockscreener-App
35.48
0.88%
0.31
Handel nachbörslich:
35.74
0.26
+0.73%
Tonix Pharmaceuticals Holding Corp Aktie (TNXP) Neueste Nachrichten
Tonix Pharmaceuticals Reports Promising Phase 3 Results for Fibromyalgia Treatment at EULAR 2025 - citybuzz -
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL - GuruFocus
Tonix Pharmaceuticals: Big Risk, Bigger RewardInitiating With A Buy (NASDAQ:TNXP) - Seeking Alpha
Tonix Pharma Presents Data at Rheumatology Congress - TipRanks
Tonix Pharmaceuticals (TNXP) Highlights Fibromyalgia Treatment a - GuruFocus
Tonix Pharmaceuticals (TNXP) Highlights Fibromyalgia Treatment at EULAR 2025 | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Presented Data and Analyses of - GlobeNewswire
First New Fibromyalgia Treatment in 15 Years Shows Breakthrough Results, FDA Decision Approaches - Stock Titan
Tonix Pharmaceuticals (TNXP) Welcomes New Board Member | TNXP St - GuruFocus
Tonix Pharmaceuticals Announces Appointment of Commercial - GlobeNewswire
Tonix Pharmaceuticals Strengthens Board with Appointment of Jim Hunter - citybuzz -
Tonix Pharmaceuticals Announces Appointment of Commercial Indust - GuruFocus
Tonix Pharmaceuticals Appoints James “Jim” Hunter To Board - citybiz
Tonix Pharmaceuticals (TNXP) Welcomes New Board Member | TNXP Stock News - GuruFocus
Tonix Pharma Appoints James Hunter to Board - TipRanks
Tonix Pharmaceuticals: Is The Recent Sell-Off A Buy Occasion? (NASDAQ:TNXP) - Seeking Alpha
Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors | TNXP Stock News - GuruFocus
Tonix Strengthens Board with 40-Year Pharma Veteran as FDA Decision on Fibromyalgia Drug Approaches - Stock Titan
Tonix Pharmaceuticals (TNXP) Files for $500M Mixed Securities Sh - GuruFocus
Tonix Pharmaceuticals stock falls after announcing $225 million share offerings By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals stock falls after announcing $225 million share offerings - Investing.com Nigeria
Tonix Pharmaceuticals (TNXP) Drops After $500M Shelf Filing - GuruFocus
Tonix Pharmaceuticals (TNXP) Files To Raise $500 Million, Shares Tumble - Benzinga
Tonix Pharma Stock Plunges 20% Pre-market On Share Sale Announcement, But Retail’s Not Pessimistic By Stocktwits - Investing.com India
Oxford Industries, GameStop, Boeing And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Why Oracle Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Tonix Pharmaceuticals (TNXP) Files for $500M Mixed Securities Shelf | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Plans Potential Share Sale of Up to $150 Million; Stock Falls Premarket - MarketScreener
Tonix Pharma Signs Major Sales Agreements for Funding - TipRanks
Tonix Pharmaceuticals Holding May Sell Up To $150 Million In Common Stock - marketscreener.com
Tonix Pharmaceuticals to Showcase Innovations at 2025 BIO International Convention - citybuzz -
(TNXP) Long Term Investment Analysis - news.stocktradersdaily.com
Tonix Pharmaceuticals Announces Presentation at the 2025 BIO Int - GuruFocus
Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention - The Manila Times
Tonix Fibromyalgia Drug Faces Critical FDA Decision: CEO to Present Latest Data at BIO 2025 - Stock Titan
Analysis of Tonix Pharmaceuticals (TNXP) Stock: Performance, News for June 2025 - Investing.com India
Tonix Pharmaceuticals doses first patient in Phase 2 OASIS trial for acute stress reaction - Proactive Investors
Tonix Pharmaceuticals to Showcase Rheumatologic Research at EULAR 2025 - citybuzz -
Tonix Pharmaceuticals Announces Poster Presentation at the Annua - GuruFocus
Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025 | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Announces Poster Presentation at the - GlobeNewswire
Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025 - The Manila Times
Tonix New Fibromyalgia Drug Shows Dual Sleep and Pain Benefits at EULAR 2025 | TNXP Stock News - Stock Titan
Northern Trust Corp Acquires New Shares in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) - Defense World
Tonix Pharmaceuticals (TNXP) Price Target Raised to $65 by Alliance Global Partners | TNXP Stock News - GuruFocus
Wall Street Zen Downgrades Tonix Pharmaceuticals (NASDAQ:TNXP) to Sell - Defense World
Tonix Pharmaceuticals: August PDUFA Date For Fibromyalgia Med A Risky Bet (NASDAQ:TNXP) - Seeking Alpha
Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights - Revista ADVFN
How the (TNXP) price action is used to our Advantage - news.stocktradersdaily.com
Tonix Pharmaceuticals (TNXP) Stock Surges Over 10%: What's Fueling the Rally and What's Next? - Daily Chhattisgarh News
What's Going On With Tonix Pharmaceuticals Stock? - Benzinga
TNXP: Preparations Continue for Potential Commercial Launch of TNX-102 SL in Fibromyalgia… - Yahoo Finance
Tonix Pharmaceuticals CEO Highlights Strategic Vision at Healthcare Showcase - citybuzz -
Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase - GlobeNewswire
Tonix begins trial for stress reaction treatment By Investing.com - Investing.com South Africa
Tonix begins trial for stress reaction treatment - Investing.com Australia
Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 O - GuruFocus
Tonix Pharmaceuticals (TNXP) Commences Phase 2 Trial for Stress Disorder Treatment | TNXP Stock News - GuruFocus
0.68%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):